RU2013111678A - Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение - Google Patents

Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение Download PDF

Info

Publication number
RU2013111678A
RU2013111678A RU2013111678/15A RU2013111678A RU2013111678A RU 2013111678 A RU2013111678 A RU 2013111678A RU 2013111678/15 A RU2013111678/15 A RU 2013111678/15A RU 2013111678 A RU2013111678 A RU 2013111678A RU 2013111678 A RU2013111678 A RU 2013111678A
Authority
RU
Russia
Prior art keywords
solution
seq
detergent
amino acid
protein
Prior art date
Application number
RU2013111678/15A
Other languages
English (en)
Russian (ru)
Inventor
Мартин БАДЕР
Моника Бенер
Адельберт ГРОССМАНН
Зильке МОЛЬ
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2013111678A publication Critical patent/RU2013111678A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
RU2013111678/15A 2010-08-30 2011-08-25 Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение RU2013111678A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10008995.2 2010-08-30
EP10008995 2010-08-30
PCT/EP2011/064600 WO2012028524A2 (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use

Publications (1)

Publication Number Publication Date
RU2013111678A true RU2013111678A (ru) 2014-10-10

Family

ID=44532851

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013111678/15A RU2013111678A (ru) 2010-08-30 2011-08-25 Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение

Country Status (9)

Country Link
EP (1) EP2611419A2 (zh)
JP (1) JP2013544488A (zh)
KR (1) KR20130047749A (zh)
CN (1) CN103068368A (zh)
BR (1) BR112013004397A2 (zh)
CA (1) CA2807433A1 (zh)
MX (1) MX2013001541A (zh)
RU (1) RU2013111678A (zh)
WO (1) WO2012028524A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862820A1 (en) 2012-02-29 2013-09-06 F. Hoffmann-La Roche Ag On-column enzymatic cleavage
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
MX2020006800A (es) 2017-12-28 2020-09-03 Takeda Pharmaceuticals Co Lipidos cationicos.
DE202019003092U1 (de) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
CN116396358B (zh) * 2023-06-08 2023-08-29 时夕(广州)生物科技有限公司 一种骨靶向纳米脂质颗粒的制备及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
SE500941C2 (sv) 1989-08-16 1994-10-03 Algy Persson Förfarande och apparat för snittning av ett preparat
CH683101A5 (de) * 1990-09-18 1994-01-14 Biotech Australia Pty Ltd T-Zellen-Epitope.
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
US20020142953A1 (en) 2000-04-14 2002-10-03 Ballinger Dennis G. Materials and methods relating to lipid metabolism
CN1268641C (zh) * 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
CA2443365C (en) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
JP2007517057A (ja) * 2003-12-30 2007-06-28 ワイス 改善された耐容性を有する免疫原性組成物中の疎水性タンパク質の処方物
WO2005084642A1 (en) 2004-01-28 2005-09-15 Biodelivery Sciences International, Inc. Apoprotein cochleate compositions
WO2006069371A1 (en) 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US20060275356A1 (en) 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
MX2008015337A (es) 2006-06-01 2009-11-26 Inst Cardiologie Montreal Metodo y compuesto para el tratamiento de estenosis valvular.
FR2915490B1 (fr) 2007-04-26 2011-10-28 Univ Joseph Fourier Grenoble I Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire
AU2008310902A1 (en) * 2007-10-08 2009-04-16 Anaphore, Inc. Trimeric IL-1Ra
WO2009097587A2 (en) 2008-01-30 2009-08-06 The Rockefeller University Nanoscale bound bilayers, methods of use and production
KR20110042152A (ko) 2008-04-25 2011-04-25 노쓰웨스턴유니버시티 콜레스테롤을 격리시키기에 적합한 나노구조

Also Published As

Publication number Publication date
CN103068368A (zh) 2013-04-24
EP2611419A2 (en) 2013-07-10
BR112013004397A2 (pt) 2017-06-27
WO2012028524A3 (en) 2012-11-15
KR20130047749A (ko) 2013-05-08
CA2807433A1 (en) 2012-03-08
MX2013001541A (es) 2013-03-18
JP2013544488A (ja) 2013-12-19
WO2012028524A2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
RU2013111678A (ru) Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
Murphy et al. Fasciola hepatica Extracellular Vesicles isolated from excretory-secretory products using a gravity flow method modulate dendritic cell phenotype and activity
RU2012146368A (ru) Выделение нерастворимых искомых белков
CN104710511B (zh) 一种源于带鱼鱼肉蛋白的铁螯合肽及其制备方法和用途
RU2012105308A (ru) Композиции белка f rsv и способы их получения
RU2009117170A (ru) Высушенные восстановленные везикулы для фармацевтического применения
RU2019108268A (ru) Варианты химозина с улучшенными молокосвертывающими свойствами
MX2012011405A (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
DE602007011384D1 (de) Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
RU2014112343A (ru) Оставы антигенов staphylococcus aureus, содержащие адъюванты
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
RU2013156669A (ru) Промывочный раствор и способ аффинной хроматографии
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
UA108872C2 (uk) Процес приготування фармацевтичних композицій для уповільненого вивільнення аналогів соматостатину
RU2015126105A (ru) Модифицированные суперспиральные белки с улучшенными свойствами
EA201000860A1 (ru) С-с-алкилимидазолбисфосфонаты
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
RU2012143607A (ru) Способ пролиферации кардиомиоцитов с применением микро-рнк
RU2013111676A (ru) Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
BR112012022292A2 (pt) método para produção da proteína recombinante interferon solúvel sem desnaturação.
RU2018116568A (ru) Новые способы получения барусибана и его промежуточных соединений
RU2015155602A (ru) Способ получения аполипопротеина a-i (аро a-i)
MX335995B (es) Materiales aislados de proteinas de huevo y lipidos de huevo y metodos para producir los mismos.
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
NZ603012A (en) Preparation of polypeptides and salts thereof

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160114